Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma

Neuro-Oncology

Volumn 7, Issue 3, 2005, Pages 246-253

  Brem, Steven ^a,g   Grossman, Stuart A ^b   Carson, Kathryn A ^b   New, Pamela ^c   Phuphanich, Surasak ^d   Alavi, Jane B ^e   Mikkelsen, Tom ^f   Fisher, Joy D ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f HENRY FORD HEALTH SYSTEM   (United States)

^g NABTT CNS Consortium   (United States)

Author keywords

Angiogenesis; Brain tumor; Copper; Glioblastoma; Penicillamine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ASPARTATE AMINOTRANSFERASE; COPPER; PENICILLAMINE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; BRAIN RADIATION; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPPER BLOOD LEVEL; COPPER DEFICIENCY; DEMENTIA; DIET THERAPY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; INSOMNIA; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MYOSITIS; NEUROLOGIC DISEASE; NEUTROPENIA; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL; PLEURAL PAIN; PROGNOSIS; SEIZURE; SEPSIS; SUBSTITUTION THERAPY; THROMBOCYTOPENIA; THROMBOEMBOLISM; VASCULITIS; VOMITING; WOUND HEALING IMPAIRMENT;

BRAIN NEOPLASMS; CHELATING AGENTS; COPPER; DIET THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PENICILLAMINE; SURVIVAL ANALYSIS;

EID: 23144467529     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/S1152851704000869     Document Type: Article

References (58)

1. Alpern-Elran, H., and Brem, S. (1985) Angiogenesis in human brain tumors: Inhibition by copper depletion. Surg. Forum 36, 498-500.
2. Bagley, R.G., Walter-Yohrling, J., Cao, X., Weber, W., Simons, B., Cook, B.P., Chartrand, S.D., Wang, C., Madden, S.L., and Teicher, B.A. (2003) Endothelial precursor cells as a model of tumor endothelium: Characterization and comparison with mature endothelial cells. Cancer Res. 63, 5866-5873.
3. Barker, F.G., 2nd, Chang, S.M., Larson, D.A., Sneed, P.K., Wara, W.M., Wilson, C.B., and Prados, M.D. (2001) Age and radiation response in glioblastoma multiforme. Neurosurgery 49, 1288-1298.
4. Bauer, K.S., Dixon, S.C., and Figg, W.D. (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 55, 1827-1834.
5. Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F., Scaglione, F., Landre, J., Pluderi, M., Tomei, G., Villani, R., Carroll, R.S., Black, P.M., and Bikfalvi, A. (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 61, 7501-7506.
6. Brat, D.J., Castellano-Sanchez, A., Kaur, B., and Van Meir, E.G. (2002) Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv. Anat. Pathol. 9, 24-36.
7. Brem, H., Ehrlich, P., Tsakayannis, D., and Folkman, J. (1997) Delay of wound healing by the angiogenesis inhibitor TNP-470. Surg. Forum 48, 714-716.
8. Brem, S. (2004) Angiogenesis and brain tumors. In: Winn, H.R. (Ed.), You-mans Neurological Surgery. Philadelphia: Saunders, pp. 771-789.
9. Brem, S., and Wotoczek-Obadia, M. (2001) Potential synergistic effect of copper reduction, anti-angiogenesis therapy and cytotoxic chemotherapy (BCNU) in a rat brain tumor model. Proc. Am. Assoc. Cancer Res. 42, 582p (abstract 3123).
10. Brem, S., Cotran, R., and Folkman, J. (1972) Tumor angiogenesis: A quantitative method for histologic grading. J. Natl. Cancer Inst. 48, 347-356.
11. Brem, S.S., Zagzag, D., Tsanaclis, A.M., Gately, S., Elkouby, M.P., and Brien, S.E. (1990a) Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic factor. Am. J. Pathol. 137, 1121-1142.
12. Brem, S., Tsanaclis, A.M., and Zagzag, D. (1990b) Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma in the rat brain. Neurosurgery 26, 391-396.
13. Carmeliet, P., and Jain, R.K. (2000) Angiogenesis in cancer and other diseases. Nature 407, 249-257.
14. Coates, R.J., Weiss, N.S., Daling, J.R., Rettmer, R.L., and Warnick, G.R. (1989) Cancer risk in relation to serum copper levels. Cancer Res. 49, 4353-4356.
15. Cox, D.R. (1972) Regression models and life tables. J. R. Stat. Soc. B. 34, 187-220.
16. Davis, F.G., Freels, S., Grutsch, J., Barlas, S., and Brem, S. (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg. 88, 1-10.
17. DeVore, R.F., Fehrenbacher, L., Herbst, R.S., Langer, C.J., Kelly, K., Gaudreault, J., Holmgren, E., Novotny, W.F., and Kabbinavar, F. (2000) A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC. Proc. Am. Soc. Clin. Oncol. 19, 485a (abstract 1896).
18. Diez, M., Cerdan, F.J., Arroyo, M., and Balibrea, J.L. (1989) Use of copper/zinc ratio in the diagnosis of lung cancer. Cancer 63, 726-730.
19. Fine, H.A., Figg, W.D., Jaeckle, K., Wen, P.Y., Kyritsis, A.P., Loeffler, J.S., Levin, V.A., Black, P.M., Kaplan, R., Pluda, J.M., and Yung, W.K. (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 18, 708-715.
20. Fine, H.A., Wen, P.Y., Maher, E.A., Viscosi, E., Batchelor, T., Lakhani, N., Figg, W.D., Purow, B.W., and Borkowf, C.B. (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J. Clin. Oncol. 21, 2299-2304.
21. Godard, S., Getz, G., Delorenzi, M., Farmer, P., Kobayahsi, H., Desbaillets, I., Nozaki, M., Diserens, A.C., Hamou, M.F., Dietrich, P.Y., Regli, L., Janzer, R.C., Bucher, P., Stupp, R., de Tribolet, N., Domany, E., and Hegi, M.E. (2003) Classification of human astrocytic gliomas on the basis of gene expression: A correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 63, 6613-6625.
22. Grossman, S.A., and Batara J. (2004) Current management of glioblastoma multiforme. Semin. Oncol. 31, 635-644.
23. Grossman, S.A., Carson, K., Piantadosi, S. and Fisher, J. (2002) Survival of adults with newly diagnosed glioblastoma multiforme (GBM) treated with experimental agents and delayed radiation therapy (RT) versus experimental agents and immediate radiation: The experience of the NABTT CNS consortium. Presented at the American Society of Clinical Oncology Annual Meeting, Orlando, Florida, May 18-21 (abstract 282). Available at: http://www.asco.org.
24. Hourani, B.T., and Demopoulos, H.B. (1969) Inhibition of S-91 mouse melanoma metastases and growth by D-penicillamine. Lab. Invest. 21, 434-438.
25. Hu, G.F. (1998) Copper stimulates proliferation of human endothelial cells under culture. J. Cell Biochem. 69, 326-335.
26. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
27. Jain, R.K. (2001) Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 7, 987-989.
28. Jong-Hon, K., Togashi, Y., Kasai, H., Hosokawa, M., and Takeichi, N. (1993) Prevention of spontaneous hepatocellular carcinoma in Long-Evans cinnamon rats with hereditary hepatitis by the administration of D-penicillamine. Hepatology 18, 614-620.
29. Joyce, D.A. (1989) D-Penicillamine pharmacokinetics and pharmacodynamics in man. Pharmacol. Ther. 42, 405-427.
30. Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G., Griffing, S., and Bergsland, E. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60-65.
31. Kalbfleisch, J.D., and Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons.
32. Kaplan, E.L., and Meier, P. (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
33. Kerbel, R.S. (2001) Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results. J. Clin. Oncol. 19, 45S-51S.
34. Khan, M.K., Miller, M.W., Taylor, J., Gill, N.K., Dick, R.D., Van Golen, K., Brew, G.J., and Merajver, S.D. (2002) Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 4, 164-170.
35. Lacroix, M., Abi-Said, D., Fourney, D.R., Gokaslan, Z.L., Shi, W., DeMonte, F., Lang, F.F., McCutcheon, I.E., Hassenbusch, S.J., Holland, E., Hess, K., Michael, C., Miller, D., and Sawaya, R. (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J. Neurosurg. 95, 190-198.
36. Linder, M.C., and Hazegh-Azam, M. (1996) Copper biochemistry and molecular biology. Am. J. Clin. Nutr. 63, 797S-811S.
37. Littman, M.L., Taguchi, T., and Shimizu, Y. (1963) Acceleration of growth of sarcoma 180 with pyridoxamine and retardation with penicillamine. Proc. Soc. Exp. Biol. Med. 113, 667-674.
38. Marsden, C.D. (1987) Wilson's disease. Q. J. Med. 248, 959-966.
39. Matsubara, T., Saura, R., Hirohata, K., and Ziff, M. (1989) Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J. Clin. Invest. 83, 158-167.
40. Netter, P., Bannwarth, B., Pere, P., and Nicolas, A. (1987) Clinical pharmacokinetics of D-penicillamine. Clin. Pharmacokinet. 13, 317-333.
41. Pan, Q., Kleer, C.G., van Golen, K.L., Irani, J., Bottema, K.M., Bias, C., De Carvalho, M., Mesri, E.A., Robins, D.M., Dick, R.D., Brewer, G.J., and Merajver, S.D. (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 62, 4854-4859.
42. Puduvalli, V.K., and Sawaya, R. (2000) Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors. J. Neurooncol. 50, 189-200.
43. Redman, B.G., Esper, P., Pan, Q., Dunn, R.L., Hussain, H.K., Chenevert, T., Brewer, G.J., and Merajver, S.D. (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin. Cancer Res. 9, 1666-1672.
44. Schiff, D. (1996) Pneumocystis pneumonia in brain tumor patients: Risk factors and clinical features. J. Neurooncol. 27, 235-240.
45. Singh, G., Fries, J.F., Williams, C.A., Zatarain, E., Spitz, P., and Bloch, D.A. (1991) Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J. Rheumatol. 18, 188-194.
46. Smith, D.B., and Gallagher, B.B. (1970) The effect of penicillamine on seizure threshold. The role of pyridoxine. Arch. Neurol. 23, 59-62.
47. Sproull, M., Brechbiel, M., and Camphausen, K. (2003) Antiangiogenic therapy through copper chelation. Expert Opin. Ther. Targets 7, 405-409.
48. Strausak, D., Mercer, J.F., Dieter, H.H., Stremmel, W., and Multhaup, G. (2001) Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res. Bull. 55, 175-185.
49. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M., Brandes, A.A., Cairncross, G., Lacombe, D., and Mirimanoff, R.O. (2004) Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. J. Clin. Oncol. 22 (14S), 2 (abstract).
50. Takano, S., Gately, S., Engelhard, H., Tsanaclis, A.M., and Brem, S. (1994) Suramin inhibits glioma cell proliferation in vitro and in the brain. J. Neurooncol. 21, 189-201.
51. Turecky, L., Kalina, P., Uhlikova, E., Namerova, S., and Krizko, J. (1984) Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin. Wochenschr. 62, 187-189.
52. Turnlund, J.R., Scott, K.C., Peiffer, G.L., Jang, A.M., Keyes, W.R., Keen, C.L., and Sakanashi, T.M. (1997) Copper status of young men consuming a low-copper diet. Am. J. Clin. Nutr. 65, 72-78.
53. Weindruch, R., and Walford, R.L. (1982) Dietary restriction in mice beginning at 1 year of age: Effect on life-span and spontaneous cancer incidence. Science 215, 1415-1418.
54. Westphal, M., Hilt, D.C., Bortey, E., Delavault, P., Olivares, R., Warnke, P.C., Whittle, I.R., Jääskeläinen, J., and Ram, Z. (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol. 5, 79-88.
55. Williams, S.R. (1993) Nutrition and Diet Therapy, 7th ed. St. Louis: Mosby-Year Book, Inc., pp. 253-268.
56. Yoshida, D., Ikeda, Y., and Nakazawa, S. (1995) Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 37, 287-293.
57. Yoshii, J., Yoshiji, H., Kuriyama, S., Ikenaka, Y., Noguchi, R., Okuda, H., Tsujinoue, H,, Nakatani, T., Kishida, H., Nakae, D., Gomez, D.E., DeLorenzo, M.S, Tejera, A.M., and Fukui, H. (2001) The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int. J. Cancer 94, 768-773.
58. Ziche, M., Jones, J., and Gullino, P.M. (1982) Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. 69, 475-482.